Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EARLY: Aggrenox in Acute Ischaemic Stroke
NCT00562588Phase 4Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2007
- Primary completion
- Feb 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of dipyridamole in ischemic stroke (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Modified Rankin Scale at 90 days. Started Jul 2007; status: completed.
02
Drugs
dipyridamole
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT00562588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00562588.